Documents
Application Sponsors
NDA 213973 | DECIPHERA PHARMACEUTICALS LLC | |
Marketing Status
Application Products
001 | TABLET;ORAL | 150MG | 2 | QINLOCK | RIPRETINIB |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2020-05-15 | PRIORITY |
LABELING; Labeling | SUPPL | 3 | AP | 2022-09-15 | STANDARD |
LABELING; Labeling | SUPPL | 4 | AP | 2022-12-29 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 7 |
SUPPL | 3 | Null | 15 |
SUPPL | 4 | Null | 2 |
TE Codes
CDER Filings
DECIPHERA PHARMS
cder:Array
(
[0] => Array
(
[ApplNo] => 213973
[companyName] => DECIPHERA PHARMS
[docInserts] => ["",""]
[products] => [{"drugName":"QINLOCK","activeIngredients":"RIPRETINIB","strength":"50MG","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"05\/15\/2020","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/213973s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"05\/15\/2020","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/213973s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/213973Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2020\\\/213973Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2020-05-15
)
)